October 9, 2012

Media Release

Meningitis Outbreak Leads to Suspension of Pharmacy License

Columbus, Ohio (Franklin County) - Ohio State Board of Pharmacy Director Kyle Parker announced the summary suspension of the Ohio Terminal Distributor of Dangerous Drugs license for the New England Compounding Center, effective October 9, 2012.

In discussions with the Ohio Department of Health and in light of an investigation conducted by the Centers for Disease Control and the U.S. Food and Drug Administration into New England Compounding Center’s contaminated methylprednisolone acetate injections, which allegedly resulted in a fungal meningitis outbreak that has affected people in nine states and leaving eight people dead, the Ohio State Board of Pharmacy found that there was clear and convincing evidence that the continuation of New England Compounding Center’s professional practice presented a danger of immediate and serious harm to others. These allegedly contaminated methylprednisolone acetate injections were administered to approximately 430 people in Ohio.

The Ohio State Board of Pharmacy will additionally conduct an investigation into the aforementioned allegations against New England Compounding Center, which is located in Framingham, Massachusetts.